Last reviewed · How we verify
NCT03915808
The Effects of Supplementation of Conjugated Linoleic Acid on Body Fat Reduction
NA trial testing Conjugated linoleic acid group in Obesity in 66 participants. Completed in 21 July 2019.
21 June 2019
Quick facts
| Lead sponsor | Jiaomei Yang |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 66 |
| Start date | 27 March 2019 |
| Primary completion | 21 June 2019 |
| Estimated completion | 21 July 2019 |
| Sites | 1 location across China |
Drugs / interventions tested
- Conjugated linoleic acid group
- Sunflower oil group
Conditions studied
Sponsor
Jiaomei Yang
Who can join
Adults 18 to 45, any sex, with Obesity or Adiposity. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a double-blinded randomized controlled trial, to evaluate the effectiveness of daily supplementation of 3.2 g CLA on body fat reduction and lipid profile in overweight or obese Chinese adults, during a lifestyle counselling-based weight loss.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Conjugated linoleic acid supplements preserve muscle in high-body-fat adults: A double-blind, randomized, placebo trial.
Chang H, Gan W, Liao X, Wei J, et al · · 2020 · cited 16× · PMID 32684362 · DOI 10.1016/j.numecd.2020.05.029 -
Conjugated Linoleic Acid Supplementation Suppresses the De Novo Lipogenesis in Adults With High Body Fat: A Double-Blind, Randomized, Placebo-Controlled Trial.
Jia K, She Y, He Y, He J, et al · · 2025 · cited 1× · PMID 41169023 · DOI 10.1002/mnfr.70306
Verify or expand the search:
- PubMed search for NCT03915808
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Obesity
Currently open trials in the same condition.
- NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
- NCT07509307 — AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee · Phase 3 · recruiting
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07481630 — A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoart · Phase 3 · recruiting
- NCT07527195 — Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscl · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03915808 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiaomei Yang
- Last refreshed: 28 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03915808.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing